51. Scleroderma Clinical trials / Disease details

Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04387825 (ClinicalTrials.gov)	August 13, 2015	10/5/2020	Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis	Lipograft Safety Enriched With Vascular Stromal Fraction Derived From Adipose Tissue, to Treatment of Digital Joint Fibrosis and Refractory Ischemic Digital Ulcers Caused by Systemic Sclerosis	Systemic Sclerosis	Drug: ADSVF application in the right hand	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	National Council of Science and Technology, Mexico	Completed	18 Years	N/A	All	20	Phase 2	Mexico
2	NCT01748084 (ClinicalTrials.gov)	April 9, 2013	10/12/2012	Rituximab in Systemic Sclerosis	Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis	Systemic Sclerosis	Drug: Rituximab;Drug: Placebo (NaCl)	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	80 Years	All	22	Phase 2/Phase 3	France
3	NCT00428883 (ClinicalTrials.gov)	January 2007	29/1/2007	High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis	Rare Disease With Microvascular Involvement: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis	Scleroderma, Diffuse	Drug: N-acetylcysteine (NAC)	Università Politecnica delle Marche	NULL	Recruiting	18 Years	80 Years	Both	45	Phase 2/Phase 3	Italy